Pf Prism Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PF PRISM, and when can generic versions of PF PRISM drugs launch?
PF PRISM has sixteen approved drugs.
There are twenty-nine US patents protecting PF PRISM drugs.
There are six hundred and thirteen patent family members on PF PRISM drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.
Summary for Pf Prism
International Patents: | 613 |
US Patents: | 29 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 16 |
Patent Litigation for Pf Prism: | See patent lawsuits for Pf Prism |
Drugs and US Patents for Pf Prism
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-002 | Sep 4, 2012 | RX | Yes | No | 7,919,625*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | XALKORI | crizotinib | CAPSULE;ORAL | 202570-001 | Aug 26, 2011 | RX | Yes | No | 7,825,137 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-001 | Sep 26, 2023 | RX | Yes | No | 7,417,148*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-002 | Sep 4, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | RX | Yes | No | 11,103,497*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-002 | Sep 26, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pf Prism
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-002 | May 30, 2018 | 7,842,699 | ⤷ Try a Trial |
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-001 | Aug 25, 2000 | 5,100,899*PED | ⤷ Try a Trial |
Pf Prism Cv | TORISEL | temsirolimus | SOLUTION;INTRAVENOUS | 022088-001 | May 30, 2007 | RE44768*PED | ⤷ Try a Trial |
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | 6,673,838 | ⤷ Try a Trial |
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-002 | Sep 4, 2012 | 6,002,008 | ⤷ Try a Trial |
Pf Prism Cv | RAPAMUNE | sirolimus | SOLUTION;ORAL | 021083-001 | Sep 15, 1999 | 5,212,155*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PF PRISM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2008-09-12 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2010-10-08 |
➤ Subscribe | Injection | 25 mg/mL, 1.8 mL vial | ➤ Subscribe | 2011-05-25 |
➤ Subscribe | Tablets | 0.5 mg | ➤ Subscribe | 2010-08-25 |
➤ Subscribe | Extended-release Tablets | 25 mg | ➤ Subscribe | 2015-05-08 |
➤ Subscribe | Tablets | 1 mg and 5 mg | ➤ Subscribe | 2018-02-23 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2018-10-15 |
➤ Subscribe | Tablets | 50 mg and 200 mg | ➤ Subscribe | 2008-04-14 |
➤ Subscribe | For Injection | 50 mg per vial | ➤ Subscribe | 2009-06-15 |
➤ Subscribe | Tablets | 1 mg and 2 mg | ➤ Subscribe | 2009-12-17 |
➤ Subscribe | Extended-release Tablets | 50 mg and 100 mg | ➤ Subscribe | 2012-02-29 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-10 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Tablets | 100mg and 500mg | ➤ Subscribe | 2016-09-06 |
International Patents for Pf Prism Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Norway | 332188 | ⤷ Try a Trial |
Brazil | PI0608464 | ⤷ Try a Trial |
Hong Kong | 1114614 | ⤷ Try a Trial |
Poland | 3498734 | ⤷ Try a Trial |
European Patent Office | 2133325 | ⤷ Try a Trial |
European Patent Office | 3106164 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pf Prism Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1786785 | 449 | Finland | ⤷ Try a Trial | |
1786785 | 13C0015 | France | ⤷ Try a Trial | PRODUCT NAME: CRIZOTINIB ET SES SELS, HYDRATES ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/793/001 20121026 |
0648494 | 24/2001 | Austria | ⤷ Try a Trial | PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926 |
0763039 | 08C0018 | France | ⤷ Try a Trial | PRODUCT NAME: TEMSIROLIMUS; REGISTRATION NO/DATE: EU/1/07/424/001 20071119 |
1786785 | 122013000027 | Germany | ⤷ Try a Trial | PRODUCT NAME: CRIZOTINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023 |
0648494 | C00648494/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: SIROLIMUS; REGISTRATION NO/DATE: IKS 55243 20000926 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.